SAT-046 Insulin-Like Growth Factor and Fibroblast Growth Factor 21 in Men with Klinefelter Syndrome

Abstract Background: Men with 47, XXY Klinefelter syndrome (KS) commonly present with obesity, metabolic disorders, and insulin insensitivity. The insulin-like growth factor (IGF) system has pleiotropic effects including regulation of glucose metabolism. Fibroblast growth factor 21 (FGF21) is associated with weight loss and favourable metabolic changes, but patients with obesity or type 2 diabetes might be resistant to this effect despite presenting with increased levels. Aim: To describe levels of components in the IGF system and FGF21 among men with KS, either treated or not treated with testosterone supplementation therapy (TT), in comparison with control males. Methods: A total of 66 men with KS were included, 33 without current TT and 33 with current TT. A control group of 70 healthy age-matched males were included. Serum levels of insulin-like growth factor 1 (IGF-1), insulin-like growth factor-binding protein 3 (IGFBP3), pregnancy-associated plasma protein A (PAPP-A), FGF21, and fibroblast activation protein (FAP) were compared between the three groups applying the Kruskal-Wallis test. Results: Levels of (IGF-1 µg/L) were not different between the groups (median (25-75 %), untreated KS 162 (140-201.5), treated KS 165 (128.5-215), controls 176.5 (150.8-214.5), p=0.5). Similarly, FGF21 levels (ng/L) were comparable between the groups (median (25-75 %), untreated KS 84.7 (53.3-217.6), treated KS 97.2 (56.4-224.8), controls 100.3 (66.0-191.0), p=0.9). Levels of IGFBP3, PAPP-A and FAP were also found to be comparable between the groups (p≥0.2). Conclusion: This was the first study investigating FGF21 in men with KS. Our results indicate that regulation of the IGF-1 system and levels of FGF21 are not altered in men with KS compared with age-matched controls, and that TT in men with KS does not affect these systems.

Download Full-text

HIGHER SERUM LEVELS OF FIBROBLAST GROWTH FACTOR 21 IN GERIATRIC PATIENTS WITH CACHEXIA

Innovation in Aging ◽

10.1093/geroni/igy023.1104 ◽

2018 ◽

Vol 2 (suppl_1) ◽

pp. 300-300

Author(s):

K Franz ◽

M Ost ◽

C Herpich ◽

L Otten ◽

V Coleman ◽

...

Keyword(s):

Growth Factor ◽

Fibroblast Growth Factor ◽

Geriatric Patients ◽

Serum Levels ◽

Fibroblast Growth Factor 21 ◽

Fibroblast Growth

Download Full-text

Higher serum levels of fibroblast growth factor 21 in old patients with cachexia

Nutrition ◽

10.1016/j.nut.2018.11.004 ◽

2019 ◽

Vol 63-64 ◽

pp. 81-86 ◽

Cited By ~ 4

Author(s):

Kristina Franz ◽

Mario Ost ◽

Lindsey Otten ◽

Catrin Herpich ◽

Verena Coleman ◽

...

Keyword(s):

Growth Factor ◽

Fibroblast Growth Factor ◽

Serum Levels ◽

Fibroblast Growth Factor 21 ◽

Fibroblast Growth ◽

Old Patients

Download Full-text

Effect of Fibroblast Growth Factor 21 on the Expression of TLR4 and BAMBI Genes in Cholesterol-Treated Human Hepatic Stellate Cells

Jentashapir Journal of Cellular and Molecular Biology ◽

10.5812/jjcmb.113672 ◽

2021 ◽

Vol 12 (3) ◽

Author(s):

Elham Shakerian ◽

Narges Mohammad Taghvaei ◽

Zohre Askari ◽

Reza Afarin

Keyword(s):

Growth Factor ◽

Mrna Expression ◽

Fibroblast Growth Factor ◽

Hepatic Stellate Cells ◽

Stellate Cells ◽

Fibroblast Growth Factor 21 ◽

Control Group ◽

Type I ◽

Fibroblast Growth ◽

Human Hscs

Background: Activated hepatic stellate cells (HSCs) are the primary mediators in the progression of hepatic fibrosis. The activation of toll-like receptor 4 (TLR4) signaling leads to the downregulation of the transmembrane inhibitory transforming growth factor-beta (TGF-β) pseudoreceptor BMP and activin membrane-bound inhibitor (BAMBI) on HSCs. Fibroblast growth factor 21 (FGF21) is a natural secretory protein in the body with effects, such as the reduction of fat accumulation and oxidation of lipids; however; no study has investigated FGF21 ability to prevent the progression of liver fibrosis. Objectives: This study aimed to examine the beneficial effects of FGF21 to reduce cholesterol-activated human HSCs. Methods: The human HSCs were incubated in media containing different concentrations of cholesterol, including 25, 50, 75, 100, 125, and 150 μM, for 24 h and then incubated with FGF21 for 24 h. Total ribonucleic acids were extracted and reversely transcribed into complementary deoxyribonucleic acid. A quantitative real-time polymerase chain reaction was performed in this study. Results: The results showed that the messenger ribonucleic acid (mRNA) expression of TGF-β, collagen, type I, alpha 1 (collagen1α), and TLR4 genes increased significantly in the presence of cholesterol (75 and 100 μM), compared to that of the control group (* P < 0.05, ** P < 0.01, and *** P < 0.001); nevertheless, the mRNA expression of the BAMBI gene significantly reduced, compared to that of the control group (* P < 0.05). The FGF21 significantly reduced the mRNA expression of TGF-β, collagen1α, and TLR4 genes (# P < 0.05). The mRNA expression of the BAMBI gene significantly increased with FGF21 (# P < 0.05). Conclusions: It was concluded that the treatment with FGF21 reduces the cholesterol-activated HSCs by decreasing the mRNA expression of the TLR4, TGF-β, and collagen1α genes and increasing the mRNA expression of the BAMBI gene.

Download Full-text

Serum levels of the adipokine fibroblast growth factor-21 are increased in preeclampsia

Cytokine ◽

10.1016/j.cyto.2013.02.019 ◽

2013 ◽

Vol 62 (2) ◽

pp. 322-326 ◽

Cited By ~ 23

Author(s):

Holger Stepan ◽

Karoline Kley ◽

Janka Hindricks ◽

Susan Kralisch ◽

Alexander Jank ◽

...

Keyword(s):

Growth Factor ◽

Fibroblast Growth Factor ◽

Serum Levels ◽

Fibroblast Growth Factor 21 ◽

Fibroblast Growth

Download Full-text

Fibroblast Growth Factor 21 in Patients with Acromegaly

Experimental and Clinical Endocrinology & Diabetes ◽

10.1055/s-0043-115647 ◽

2017 ◽

Vol 125 (10) ◽

pp. 649-654 ◽

Cited By ~ 3

Author(s):

Jowita Halupczok-Żyła ◽

Aleksandra Jawiarczyk-Przybyłowska ◽

Marek Skrzypski ◽

Mathias Strowski ◽

Marek Bolanowski

Keyword(s):

Growth Factor ◽

Disease Activity ◽

Fibroblast Growth Factor ◽

Body Mass ◽

Hdl Cholesterol ◽

Fibroblast Growth Factor 21 ◽

Control Group ◽

Fibroblast Growth ◽

Anthropometric Parameters ◽

Cholesterol Levels

Abstract Introduction The goal of the study was to investigate fibroblast growth factor-21 (FGF-21) levels in acromegalic patients in relation to the disease activity and to compare them with controls. Further, we aimed to evaluate the associations between FGF-21 and random growth hormone (GH), insulin-like growth factor-1 (IGF-1), metabolic and anthropometric parameters. Materials and methods The study group consisted of 50 acromegalic patients divided into 3 subgroups on the basis of disease activity (AA – active acromegaly, CD – controlled disease, CA – cured acromegaly). 27 subjects were assigned to the control group (CG). Blood samples were obtained from all participants to assess FGF-21, GH, IGF-1, lipids, glucose and insulin levels. Body mass, body mass index and body composition were also evaluated. Results There were no statistically significant differences in FGF-21 concentrations across all groups despite of subjects classification. FGF-21 correlated positively with random GH in the groups: CA, CD+CA, AA+CD+CA (r=0.48, p=0.049; r=0.39, p=0.023; r=0.33, p=0.02; respectively); with IGF-1 in the AA+CD+CA group (r=0.29, p=0.041); with triglycerides in the following groups: CD, CD+CA, AA+CD+CA (r=0.63, p=0.08; r=0.44, p=0.01; r=0.37, p=0.007; respectively) and with age in the CG and CD+CA groups (r=0.41, p=0.029; r=0.42, p=0.029; respectively). There were statistically significant negative correlations between FGF-21 and HDL-cholesterol levels in the groups: CD, CD+CA, AA+CD+CA (r=-0.53, p=0.03; r=-0.37, p=0.032; r=-0.29, p=0.036, respectively). Conclusions FGF-21 levels were similar in patients with acromegaly compared to controls. However, our results indicate that FGF-21 may have a potential role in the development of acromegaly complications.

Download Full-text

Thioredoxin-1 and Correlations of the Plasma Cytokines Regarding Aortic Valve Stenosis Severity

Biomedicines ◽

10.3390/biomedicines9081041 ◽

2021 ◽

Vol 9 (8) ◽

pp. 1041

Author(s):

Peteris Tretjakovs ◽

Juris Lurins ◽

Simons Svirskis ◽

Gita Gersone ◽

Dace Lurina ◽

...

Keyword(s):

Growth Factor ◽

Aortic Valve ◽

Fibroblast Growth Factor ◽

Aortic Valve Stenosis ◽

Plasma Levels ◽

Fibroblast Growth Factor 21 ◽

Control Group ◽

Fibroblast Growth ◽

Local Inflammatory Response ◽

Thioredoxin 1

Aortic valve stenosis (AS) develops not only with a pronounced local inflammatory response, but also oxidative stress is involved. The aim of this study was to evaluate the plasma levels of thioredoxin-1 (TRX1), myeloperoxidase (MPO), chemerin, growth differentiation factor 15 (GDF-15), angiopoietin-2 (Ang-2), vascular endothelial growth factor A (VEGF-A), fibroblast growth factor 2 (FGF-2), fibroblast growth factor 21 (FGF-21), and metalloproteinase (MMP)-1, -3, and -9 in acquired AS patients as well as to clarify the correlations of TXR1 and the plasma inflammatory biomarkers regarding AS severity. AS patients were classified into three groups: 16 patients with mild AS stenosis, 19 with moderate and 11 with severe AS, and 30 subjects without AS were selected as a control group. AS patients had significantly higher plasma levels of TRX1 compared to controls, but the highest difference was found in mild AS patients compared to the controls. We conclude that AS is associated with significantly increased plasma TRX1 levels, and TRX1 might serve as a specific and sensitive biomarker of AS. TRX1 and also chemerin, GDF-15, VEGF-A, FGF-2 and FGF-21 significantly correlate with AS severity degrees. TRX1 also showed positive association with FGF-2, VEGF-A, and MMP-3 in all AS patients.

Download Full-text

Retrospective analysis of factors associated with serum levels of fibroblast growth factor-21 in patients with diabetes

Annals of Palliative Medicine ◽

10.21037/apm-21-525 ◽

2021 ◽

Vol 10 (3) ◽

pp. 3258-3266

Author(s):

Fang Ren ◽

Jiafang Huang ◽

Tianran Dai ◽

Feng Gan

Keyword(s):

Growth Factor ◽

Fibroblast Growth Factor ◽

Retrospective Analysis ◽

Serum Levels ◽

Fibroblast Growth Factor 21 ◽

Fibroblast Growth ◽

Factors Associated ◽

Patients With Diabetes

Download Full-text

Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction

Clinical Endocrinology ◽

10.1111/cen.12380 ◽

2014 ◽

Vol 80 (6) ◽

pp. 918-924 ◽

Cited By ~ 40

Author(s):

Janka Hindricks ◽

Thomas Ebert ◽

Anette Bachmann ◽

Susan Kralisch ◽

Ulrike Lössner ◽

...

Keyword(s):

Growth Factor ◽

Renal Dysfunction ◽

Fibroblast Growth Factor ◽

Serum Levels ◽

Fibroblast Growth Factor 21 ◽

Fibroblast Growth ◽

Acute Renal Dysfunction

Download Full-text

Effects of fibroblast growth factor 21 on cell damage in vitro and atherosclerosis in vivo

Canadian Journal of Physiology and Pharmacology ◽

10.1139/cjpp-2014-0227 ◽

2014 ◽

Vol 92 (11) ◽

pp. 927-935 ◽

Cited By ~ 21

Author(s):

Wenhe Zhu ◽

Changwen Wang ◽

Lei Liu ◽

Yan Li ◽

Xiaokun Li ◽

...

Keyword(s):

Growth Factor ◽

Fibroblast Growth Factor ◽

Cell Damage ◽

Density Lipoprotein ◽

Serum Levels ◽

Lipoprotein Cholesterol ◽

Fibroblast Growth Factor 21 ◽

Fibroblast Growth

Fibroblast growth factor 21 (FGF-21), which is a modulator of glucose and lipid homeostasis, acts as a novel therapeutic reagent for many metabolic perturbations. However, its potential as a treatment for cardiovascular disease, especially atherosclerosis (AS) has not been fully explored. Here, we report that recombinant FGF-21 improves resistance to cell damage from oxidative stress in vitro, and from atherosclerosis in vivo. Human umbilical vein endothelial cells (HUVECs) were induced with H2O2, followed by treatment with high purity recombinant FGF-21. The results indicated that FGF-21 significantly enhanced cell viability and decreased the degree of DNA fragmentation in HUVECs, as caused by H2O2 stress induction. Further studies revealed that FGF-21 inhibited H2O2-induced cell apoptosis by preventing the activation of mitogen-activated protein kinase (MAPK) signaling pathways. In an established rat model, FGF-21 dramatically improved the condition of atherosclerotic rats by decreasing serum levels of total triglyceride (TG), low density lipoprotein cholesterol (LDL-C), and total cholesterol (TC), and by increasing the serum levels of high density lipoprotein cholesterol (HDL-C). FGF-21 also has antioxidant effects in the atherosclerotic rat, such that increased levels of superoxide dismutase, reduced glutathione, and reduced malondialdehyde were observed. These data provide novel insight into the potential use of FGF-21 in the prevention and treatment of human cardiovascular diseases.

Download Full-text